9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Estimated reading time: < 1 min

Condition: Pleural Mesothelioma Malignant Advanced

Estimated Enrollment: 85

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin.,  Define initial estimates of efficacy, measured by modified RECIST criteria for advanced MPM,  Determine the MTD of ADI-PEG 20 in combination with pemetrexed and cisplatin,

Interventions: ADI-PEG 20,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: May 2019

Completion Date: May 2020

Last  Posted Date: March 20, 2019

Location: Mayo Clinic Rochester, Rochester, Minnesota, United States

Website Link: https://ClinicalTrials.gov/show/NCT02029690

Was this article helpful?
Dislike 0